Ensign Peak Advisors, Inc Kymera Therapeutics, Inc. Transaction History

Ensign Peak Advisors, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$19.57 - $30.92 $143,643 - $226,952	-7,340 Reduced 15.44%	40,207 $1 Million
Q3 2022 Nov 14, 2022	BUY	$20.91 - $34.27 $23,628 - $38,725	1,130 Added 2.43%	47,547 $1.04 Million
Q2 2022 Aug 12, 2022	SELL	$14.13 - $42.55 $181,754 - $547,320	-12,863 Reduced 21.7%	46,417 $914,000
Q4 2021 Feb 11, 2022	BUY	$49.91 - $65.56 $1.32 Million - $1.74 Million	26,540 Added 81.06%	59,280 $3.76 Million
Q3 2021 Nov 12, 2021	SELL	$47.8 - $66.66 $1.43 Million - $2 Million	-30,000 Reduced 47.82%	32,740 $1.92 Million
Q1 2021 May 12, 2021	BUY	$35.64 - $85.46 $1.52 Million - $3.65 Million	42,740 Added 213.7%	62,740 $2.44 Million
Q3 2020 Nov 12, 2020	BUY	$26.1 - $33.28 $522,000 - $665,600	20,000 New	20,000 $646,000

184

64.4M

50.6K

81.7K

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.3B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.